Moreover, in cytogenetics risk-intermediate (HR = 2.133, p = 0.0106) and cytogenetics risk-poor (HR = 3.312, p = 0.0371) subgroups, the expression of SH3BP5 also inversely correlated with the overall survival of AML patients (Figure 3C–E). This evidence concerns the gene SH3BP5 and acute myeloid leukemia.